Welcome to Trends-in-Medicine, offering independent, cutting-edge articles and information on drugs and devices in development. Our subscribers have access to news and analysis on the latest data, regulatory issues, and trends of interest to the healthcare community.

Alzheimer's Update

The data on Eisai and Biogen’s Leqembi (lecanemab) was the highlight of the Clinical Trials on Alzheimer's Disease (CTAD) meeting in Boston. Here we dive into the data.

Retina Update

Three new drugs for geographic atrophy had mixed news at ASRS: (10 A safety issue reported with Apellis Pharmaceuticals’ Syfovre (pegcetacoplan), a complement C3 inhibitor, (2) Efficacy questions about Astellas/Iveric Bio’s Izervay (avacincaptad pegol), a complement C5 inhibitor, and (3) an efficacy miss for Annexon Biosciences’ ANX-007, A complement C1q inhibitor. And there was positive data on sevral other drugs.

AI Perspectives

Where is artificial intelligence going in healthcare? Here is a Perpective from one of our technology-savvy reporters

De-Risking Clinical Trials?

Why do so many clinical trials fail? What can be done to reduce the number of failures? This may offer some insights in what can be done and what needs to be done.

ASCO 2023 Preview

As always, there will be a lot of data at the American Society of Clinical Oncology (ASCO) meeting, which is taking place in Chicago June 2-6, 2023. Abstracts were released on May 25, 2023, and there are (and will be) numerous reports based on those abstracts. Here we try point out some trials you may want to give special attention. We are not reporting the data, except sometimes to reference “preliminary” (meaning abstract) findings, with 2 exceptions where the actual data were released in a press conference [in cervical cancer and in myelodysplastic syndromes (MDS)]